Repligen (NASDAQ:RGEN) Shares Down 2.3%

Shares of Repligen Co. (NASDAQ:RGENGet Free Report) dropped 2.3% on Monday . The stock traded as low as $193.40 and last traded at $193.43. Approximately 24,608 shares changed hands during trading, a decline of 96% from the average daily volume of 550,311 shares. The stock had previously closed at $198.03.

Analysts Set New Price Targets

RGEN has been the subject of several research reports. Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. JPMorgan Chase & Co. raised their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, Benchmark downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Monday, December 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Check Out Our Latest Analysis on RGEN

Repligen Stock Down 0.6 %

The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The stock has a 50 day simple moving average of $194.20 and a 200 day simple moving average of $171.74. The firm has a market capitalization of $10.25 billion, a PE ratio of 255.34, a PEG ratio of 6.05 and a beta of 1.03.

Repligen (NASDAQ:RGENGet Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. The business had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business’s quarterly revenue was down 16.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. As a group, sell-side analysts forecast that Repligen Co. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 in the last ninety days. Company insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RGEN. Fortis Capital Advisors LLC purchased a new position in Repligen during the fourth quarter valued at $35,000. Park Place Capital Corp increased its position in Repligen by 90.2% during the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 120 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its position in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares during the last quarter. Signaturefd LLC increased its position in Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 86 shares during the last quarter. Finally, Principal Securities Inc. purchased a new stake in Repligen during the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.